Multiple Sclerosis Clinical Trial

An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

Summary

The purpose of this study is to determine changes on overall gait as well as in multiple gait and balance parameters after withdrawal of dalfampridine-ER 10mg in MS subjects who are receiving the medication consistently for at least two weeks prior to screening.

View Full Description

Full Description

Longitudinal study design

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of multiple sclerosis
Receiving Ampyra® consistently for at least 2 weeks prior to the screening visit
No history of seizures except simple febrile seizures

Exclusion Criteria:

Sexually active woman of childbearing potential who is not surgically sterile, Subject who is pregnant or breastfeeding

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

20

Study ID:

NCT01535664

Recruitment Status:

Completed

Sponsor:

Acorda Therapeutics

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

OMRF Multiple Sclerosis Center of Excellence
Oklahoma City Oklahoma, 73104, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

20

Study ID:

NCT01535664

Recruitment Status:

Completed

Sponsor:


Acorda Therapeutics

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider